Strategic Focus

Our strategy to target key aspects of EB

Epidermolysis bullosa (EB) has a wide range of symptoms and associated conditions. EB is not just a skin disease but has far-reaching effects on the entire body. Due to the complex clinical features of EB, research is focused on various key areas.

Current scientific focus of our R&D activities lies in addressing dystrophic and junctional EB. These are the most severe forms of EB and carry a significantly increased risk of developing cutaneous squamous cell carcinoma (SCC). 

EB is currently incurable. Our approaches are focusing on addressing skin fragility and skin tumors. In the future, we plan to expand our research efforts and target pathogenic events involved in blister and wound formation. 

In addition, we are building EB Biobank. We systematically collect and process biological samples and related donor data. This allows us to yield unprecedent insight into pathogenic events in EB and potentially identify new relevant targets for drug discovery. 

We are advancing our efforts in EB in collaboration with other research institutions and clinics as well as industry partners.